Vila J, Ruiz J, Goñi P, Jimenez de Anta T
Department of Microbiology, Hospital Clínic, School of Medicine, University of Barcelona, Spain.
J Antimicrob Chemother. 1997 Jun;39(6):757-62. doi: 10.1093/jac/39.6.757.
Mutations in the parC gene, which encodes a subunit of topoisomerase IV, were determined in 21 epidemiologically unrelated clinical isolates of Acinetobacter baumannii. Our studies highlight the conserved sequences in the quinolone-resistance-determining region of the parC gene from A. baumannii and other bacteria. Nine of ten isolates with MICs of ciprofloxacin of > or = 32 mg/L showed a change of Ser80 to Leu and one showed a change of Glu84 to Lys. These results suggest that ParC from A. baumannii is a secondary target for quinolones and that mutations at residues Ser80 and Glu84, when combined with mutations at Ser83 of GyrA, may render A. baumannii highly resistant to quinolones.
在21株流行病学上无关联的鲍曼不动杆菌临床分离株中,测定了编码拓扑异构酶IV一个亚基的parC基因的突变情况。我们的研究突出了鲍曼不动杆菌和其他细菌parC基因喹诺酮耐药决定区的保守序列。10株环丙沙星最低抑菌浓度(MIC)≥32mg/L的分离株中有9株显示Ser80变为Leu,1株显示Glu84变为Lys。这些结果表明,鲍曼不动杆菌的ParC是喹诺酮类药物的次要靶点,并且Ser80和Glu84位点的突变与GyrA的Ser83位点突变相结合时,可能使鲍曼不动杆菌对喹诺酮类药物产生高度耐药性。